Why Vertex Pharmaceuticals (VRTX) Stock Is Down Today

Vertex Pharmaceuticals (VRTX) is down 3.9% today. Here is some analysis on what might have caused this price movement. ([stockanalysis.com](https://stockanalysis.com/stocks/vrtx/history/))

Analysis: The most likely explanation is that this is a sentiment-driven pullback rather than a reaction to a new company-specific negative event. Vertex had no fresh material filing or major new announcement on October 13, while the broader biotech group was weaker, which suggests sector pressure and profit-taking may be driving the move. ([investors.vrtx.com](https://investors.vrtx.com/news-events/press-releases))

Details:

VRTX was trading at about $487.21, down 3.90%, in the afternoon on October 13, 2026. ([stockanalysis.com](https://stockanalysis.com/stocks/vrtx/history/))

The Nasdaq Biotechnology Index was down 1.84% on October 13, showing that biotech shares were under pressure more broadly. ([indexes.nasdaqomx.com](https://indexes.nasdaqomx.com/Index/Overview/NBI?mod=article_inline))

Vertex’s investor site shows its most recent press release was on October 9 about new ALYFTREK data, and another on October 7 set November 2, 2026 as the date for third-quarter results. ([investors.vrtx.com](https://investors.vrtx.com/news-events/press-releases?utm_source=openai))

The company’s filings page shows no new October 13 SEC filing, with the latest listed items being September 10 insider ownership forms and a September 1 current report. ([investors.vrtx.com](https://investors.vrtx.com/financial-information/sec-filings?field_nir_sec_cik_target_id=&field_nir_sec_date_filed_value=&items_per_page=10&items_per_page_toggle=0&mobile=1&order=field_nir_sec_description&page=339&sort=asc))

Sources:

Vertex Pharmaceuticals, SEC, Nasdaq, Stock Analysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$VRTX Insider Trading Activity

$VRTX insiders have traded $VRTX stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.

Here’s a breakdown of recent trading of $VRTX stock by insiders over the last 6 months:

CARMEN BOZIC (EVP and CMO) has made 0 purchases and 5 sales selling 14,411 shares for an estimated $6,516,733.
JOY LIU (EVP and Chief Legal Officer) has made 0 purchases and 3 sales selling 2,760 shares for an estimated $1,249,711.
DUNCAN MCKECHNIE (EVP, Chief Commercial Officer) sold 1,541 shares for an estimated $799,779
OURANIA TATSIS (EVP, Chief Reg. & Quality Off.) sold 1,500 shares for an estimated $787,485
SANGEETA N. BHATIA sold 318 shares for an estimated $134,746

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive VRTX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$VRTX Hedge Fund Activity

We have seen 855 institutional investors add shares of $VRTX stock to their portfolio, and 713 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 6,517,600 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,237,487,448
INVESCO LTD. added 5,481,995 shares (+214.1%) to their portfolio in Q2 2026, for an estimated $2,723,071,376
FRANKLIN RESOURCES INC added 2,796,121 shares (+507.3%) to their portfolio in Q2 2026, for an estimated $1,388,917,184
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 2,041,282 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,013,966,007
CAPITAL RESEARCH GLOBAL INVESTORS removed 1,635,327 shares (-7.7%) from their portfolio in Q2 2026, for an estimated $812,315,980
VICTORY CAPITAL MANAGEMENT INC removed 1,183,614 shares (-35.3%) from their portfolio in Q2 2026, for an estimated $587,936,582
ALLIANCEBERNSTEIN L.P. removed 891,471 shares (-22.8%) from their portfolio in Q2 2026, for an estimated $442,820,389

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$VRTX Congressional Stock Trading

Members of Congress have traded $VRTX stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $VRTX stock by members of Congress over the last 6 months:

REPRESENTATIVE DAVID TAYLOR sold up to $15,000 on 08/26.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$VRTX Price Targets

Multiple analysts have issued price targets for $VRTX recently. We have seen 6 analysts offer price targets for $VRTX in the last 6 months, with a median target of $571.0.

Here are some recent targets:

Brian Skorney from Baird set a target price of $350.0 on 07/07/2026
Brian Abrahams from RBC Capital set a target price of $570.0 on 07/07/2026
Eliana Merle from Barclays set a target price of $615.0 on 05/06/2026
Terence Flynn from Morgan Stanley set a target price of $616.0 on 05/05/2026
William Pickering from Bernstein set a target price of $572.0 on 05/05/2026
Whitney Ijem from Canaccord Genuity set a target price of $436.0 on 05/05/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.